539730

- Fredun Pharmaceuticals Limited's Equity Shares have been permitted to trade and admitted to dealings on the National Stock Exchange of India Limited (NSE). - Trading on NSE commences from August 17, 2026. - The company was already listed on BSE Limited.

- FY27 revenue guidance of ₹800 Cr, with an expectation to overachieve. FY26 actual revenue was ₹635 Cr against a target of ₹570 Cr. - Blended revenue growth expected at 30-35% YoY for the next 3 years, driven by new age brands (35-45% YoY) and vintage business (15-20% YoY). - GX business line projected to grow 25-35% YoY for the next 5 years. - Pet care business (including Wagr.in) targeted for 40-50% growth YoY for the next 3-4 years, aiming for ₹100 Cr revenue within 3-3.5 years. Launching cat food by Q3 FY27. - Capex plan includes ₹30-40 Cr for FY27 and ₹35-45 Cr annually for the next 2 years for manufacturing expansion. - Expect EBIT margins to reach 12-13% within the next 12 quarters, with a potential sudden spike in profitability in 8-11 quarters. - Working capital inventory days targeted to reduce to 110-125 days within the next 4 quarters. - Credit rating improved from BBB to BBB+.

- Audio recording of Q1 FY27 Earnings Conference Call held on August 13, 2026, for Un-Audited Financial Results (quarter ended June 30, 2026) is available on the company's website.

- Concall Schedule - Concall Date: 13th August, 2026 - Concall Time: 11:30 a.m.

- Consolidated Revenue ₹128.25Cr vs ₹98.87Cr (▲29.71% YoY) - EBITDA ₹13.53Cr vs ₹7.01Cr (▲93.12% YoY) - PAT ₹11.01Cr vs ₹5.47Cr (▲101.14% YoY) - EBITDA Margin 10.55% vs 7.09% (▲346bps)

- Standalone Total Income ₹228.25 Cr vs ₹119.86 Cr (▲90.44% YoY) - Standalone EBITDA ₹32.78 Cr vs ₹16.99 Cr (▲92.90% YoY) - Standalone PAT ₹13.17 Cr vs ₹6.77 Cr (▲94.63% YoY) - Standalone EBITDA Margin 14.36% vs 14.18% (▲18bps)

- Consolidated Revenue ₹227.76Cr vs ₹119.40Cr (▲90.75% YoY) - EBITDA ₹32.25Cr vs ₹₹16.54Cr (▲95.09% YoY) - PAT ₹13.13Cr vs ₹6.77Cr (▲94.09% YoY) - EBITDA Margin 14.16% vs 13.85% (▲31bps)

- Consolidated Revenue ₹22,775.55 Lakhs vs ₹11,940.29 Lakhs (▲90.75% YoY) - EBITDA ₹3,274.09 Lakhs vs ₹1,699.12 Lakhs (▲92.69% YoY) - PAT ₹1,313.23 Lakhs vs ₹676.58 Lakhs (▲94.09% YoY) - EBITDA Margin 14.34% vs 14.18% (▲16bps)

- Board meeting on August 05, 2026, to consider and approve unaudited financial results (Standalone and Consolidated) for the first quarter ended June 30, 2026. - Trading window for dealing in securities remains closed until 48 hours after the declaration of financial results.

- Fredun Pharmaceuticals Limited allotted 11,025,380 Bonus Equity Shares in a 2:1 ratio (2 new shares for every 1 existing) as of the record date July 16, 2026. - The paid-up share capital increased from ₹5,51,26,900 to ₹16,53,80,700.